2009, Number 4
<< Back
Gac Med Mex 2009; 145 (4)
Cartas al editor
Language: Spanish
References: 13
Page: 359
PDF size: 18.12 Kb.
Text Extraction
No abstract
REFERENCES
Medina-Franco H, Aguilar-Jiménez JR, Medina-Cuairán JZ. Tumores del estroma gastrointestinal. Análisis de factores pronósticos en un grupo de pacientes mexicanos. Gac Med Mex 2009;145;91-96.
Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244:176-184.
Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J, et al. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J Gastrointest Surg 2009 Mar 17 (Epub ahead of print).
Blay JY. New paradigms in gastrointestinal stromal tumour management. Ann Oncol 2009;20(Suppl 1):18-24.
Siehl J, Thiel E. C-Kit, GIST and imatinib. Recent results. Cancer Res 2007;176:145-151.
Medina-Franco H, Aguilar-Jiménez JR, Medina-Cuairán JZ. Tumores del estroma gastrointestinal. Análisis de factores pronósticos en un grupo de pacientes mexicanos. Gac Med Mex 2009;146:91-96.
Lasota J, Miettinen M. Clinical significance of oncogenetic KIT and PDGFR mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-266.
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-49.
DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stomal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.
Miettinen M, El-Rifai W, HL Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-483.
Full text